Production (Stage)
ANI Pharmaceuticals, Inc.
ANIP
$57.79
$0.520.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3.44% | 28.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.44% | 28.48% | |||
| Cost of Revenue | -9.02% | 27.28% | |||
| Gross Profit | 12.50% | 29.37% | |||
| SG&A Expenses | 8.79% | -1.08% | |||
| Depreciation & Amortization | 1.29% | 43.51% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.66% | 18.73% | |||
| Operating Income | 881.16% | 114.04% | |||
| Income Before Tax | 245.23% | 56.31% | |||
| Income Tax Expenses | 223.52% | 52.45% | |||
| Earnings from Continuing Operations | 252.60% | 57.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 252.60% | 57.48% | |||
| EBIT | 881.16% | 114.04% | |||
| EBITDA | 57.04% | 397.10% | |||
| EPS Basic | 227.31% | 56.62% | |||
| Normalized Basic EPS | 264.30% | 62.86% | |||
| EPS Diluted | 224.80% | 56.75% | |||
| Normalized Diluted EPS | 260.69% | 62.86% | |||
| Average Basic Shares Outstanding | 0.83% | 0.21% | |||
| Average Diluted Shares Outstanding | 3.09% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 1.66% | -1.35% | |||